Frazier Healthcare Partners, a US-based healthcare-focused investment firm, closed its latest fund at $525m.
Supported by existing and select new limited partners, including endowments, public/private pension funds and financial institutions globally, Frazier Healthcare Growth Buyout Fund VIII represents the firm’s first dedicated growth buyout vehicle focused exclusively on profitable healthcare companies in the lower middle market.
Investments typically take the form of thesis-driven buyouts, recapitalizations or corporate carve-outs of companies with between $5 million and $40 million of EBITDA in selectively targeted healthcare sectors.
The firm has collaborated with its operating partners to develop companies with EBITDA in excess of $100 million in the subsectors of managed care (Bravo Health), dialysis clinics (DSI Renal) and pharma services (PCI Pharma Services).
In addition to its Seattle-based growth buyout fund, the firm’s life sciences team, based in Menlo Park, Calif., recently closed on an early stage therapeutics focused fund, at $262m (read here).
Founded in 1991, Frazier Healthcare Partners has more than $2.9 billion in committed capital under management and has made investments in more than 170 companies ranging from early-stage venture investments to growth buyouts of profitable lower middle market companies across the United States, Canada and Europe.